<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611724</url>
  </required_header>
  <id_info>
    <org_study_id>ULTIMA</org_study_id>
    <nct_id>NCT04611724</nct_id>
  </id_info>
  <brief_title>A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer</brief_title>
  <official_title>A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus&#xD;
      cancer.&#xD;
&#xD;
      Patients with locally advanced, recurrent, or metastatic urachal carcinoma of bladder,&#xD;
      urachal will be enrolled this study.&#xD;
&#xD;
      Modified version of FOLFIRINOX(Oxaliplatin 85 mg/m 2, Leucovorin 400mg/m2 , irinotecan&#xD;
      150mg/m2 and 5-FU 2400mg/m2) with prophylactic pegateograstim will be continued till&#xD;
      progression, unacceptable toxicity, or till 12 cycles (24 weeks). Study drugs can be&#xD;
      administered after 12 cycles to the subjects with benefit from study medication.&#xD;
&#xD;
      Response evaluation will be done every 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>every 2 weeks up to 30 weeks.</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 2years.</time_frame>
    <description>Progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS),</measure>
    <time_frame>up to 5 years.</time_frame>
    <description>Overall survival (OS),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>After study completion (an average of 2 year)</time_frame>
    <description>Incidence of febrile neutropenia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Urachal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours</description>
    <arm_group_label>FOLFIRINOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of bladder/urachal remnant that is clinically&#xD;
             consistent with urachal cancer.&#xD;
&#xD;
        Origin in the anterior wall or dome of the bladder Predominant invasion of muscularis or&#xD;
        deeper tissues No obvious origin from the overlying urothelium (relative normal-looking&#xD;
        urothelial mucosa) No primary adenocarcinoma elsewhere&#xD;
&#xD;
          -  Patients with locally advanced, recurrent, or metastatic disease not amenable to&#xD;
             surgery, radiotherapy, or combined modality therapy with curative intent&#xD;
&#xD;
          -  No prior systemic therapy for advanced urachal cancer. For recurrent disease, previous&#xD;
             5-FU, oxaliplatin, or irinotecan chemotherapy as neoadjuvant and/or adjuvant aim is&#xD;
             allowed if it ended more than 6 months before enrollment.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1 criteria&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Age 19 years or older&#xD;
&#xD;
          -  Adequate cardiac function&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal function Hematology&#xD;
&#xD;
          -  Life expectancy more than 3 months&#xD;
&#xD;
          -  Signed and dated informed consent of document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 65&#xD;
&#xD;
          -  Previous radiotherapy to the only measurable lesion: but previous radiotherapy will be&#xD;
             permitted unless the lesion is the only measurable lesion&#xD;
&#xD;
          -  Uncontrolled CNS metastasis (brain and/or leptomeningeal metastasis)&#xD;
&#xD;
          -  Grade 2 or more peripheral neuropathy&#xD;
&#xD;
          -  Diagnosis of any serious secondary malignancy within the last 2 years, except for&#xD;
             adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma&#xD;
             of cervix uteri or prostate cancer and curatively treated thyroid cancer of any stage.&#xD;
&#xD;
          -  Pregnancy or breast feeding, or intention of becoming pregnant during study treatment&#xD;
             or within 6 months after final dose&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Clinically significant cardiac disease (heart failure, coronary artery disease, and/or&#xD;
             arrhythmia)&#xD;
&#xD;
          -  Hypersensitivity to study medication&#xD;
&#xD;
          -  treatment with a prohibited medication or anticipation of need for prohibited&#xD;
             medication ( section 5.5 )&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae -Lyun Lee, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae -Lyun Lee, Professor</last_name>
    <phone>82 2 3010 5977</phone>
    <email>jaelyun@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Lyun Lee, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/29672836/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, Okusaka T, Furuse J. A phase II study of modified FOLFIRINOX for chemotherapy-na√Øve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023. doi: 10.1007/s00280-018-3577-9. Epub 2018 Apr 9.</citation>
    <PMID>29633005</PMID>
  </reference>
  <reference>
    <citation>Kume H, Tomita K, Takahashi S, Fukutani K. Irinotecan as a new agent for urachal cancer. Urol Int. 2006;76(3):281-2.</citation>
    <PMID>16601395</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jae-Lyun Lee</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Urachal Cancer</keyword>
  <keyword>FOLFIRINOX</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

